{"success":true,"data":{"pressRelease":{"id":"170521","rtpr_id":"nGNX45qhNl-20261015","ticker":"AKTX","exchange":"NASDAQ","all_tickers":["AKTX"],"title":"Akari Therapeutics CEO Highlights Differentiated ADC Payload Strategy and Path Toward Clinical Development in New CEO Corner","author":"Globe Newswire","published_at":"2026-10-15T13:20:00.097Z","article_body":"CEO Abizer Gaslightwala discusses Akari’s novel PH1 payload strategy and\nexecution priorities supporting AKTX-101’s advancement toward planned Phase\n1 clinical development in mid-2027\n\nRecent deal activity and emerging clinical data highlighting limitations of\ncurrent ADC sequencing reinforce the increasing demand for novel ADC payloads\n\nAccess the Akari CEO Corner here\n(https://www.globenewswire.com/Tracker?data=C93df7rjfMXVbbgREmuGZLz-A2_DedJF4abgr_H7ErkWuAhaJxZhV1TqvFUpxzluzEFHQ_kmXgb__sXKmsOjOQ==)\n\nTAMPA, Fla. and LONDON, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics,\nPlc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug\nconjugates (ADCs) with a novel RNA splicing disrupting payload, today released\na new CEO Corner segment featuring President and Chief Executive Officer\nAbizer Gaslightwala discussing the Company’s differentiated ADC payload\nstrategy, recent external validation and the execution priorities supporting\nAKTX-101’s advancement toward planned Phase 1 clinical development in\nmid-2027.\n\nAt the center of the discussion is Akari’s belief that ADC payload\ndifferentiation will become increasingly important as more cancer patients\nreceive ADCs as front-line therapies and develop resistance to the current ADC\npayload classes leaving limited subsequent therapy options. Mr. Gaslightwala\ndiscusses emerging clinical data presented at major medical conferences that\nsequential treatment of ADCs utilizing the same payload class do not provide\nbenefit after treatment relapse. This is a significant growing unmet need and\nis an exclusive opportunity for Akari with its novel ADC payload that current\nand most future ADCs will not be able to access.\n\nAkari is pursuing this exclusive opportunity using its PH1 payload, a novel\nspliceosome-modulating payload, which is designed to disrupt RNA splicing in\ncancer cells through a mechanism distinct from commonly used ADC payload\nclasses.\n\nMr. Gaslightwala also describes recent external engagements and presentations\nat partnering and industry conferences in the US and China, where there was\nsignificant interest in Akari’s ADC payload and its differentiated approach.\n\n“It was important for us to gauge interest and excitement in our novel\npayload technology and its application to ADC therapies in areas of growing\nunmet needs like ADC refractory patients, and I left the conferences even more\nconvicted in our technology, strategy, and execution as a company,” said Mr.\nGaslightwala. “Across recent partner discussions and industry engagement,\nour novel PH1 payload generated meaningful interest and reinforced our belief\nthat differentiated payloads can play an increasingly important role as ADC\ntherapies continue to evolve.”\n\nMr. Gaslightwala also points to recent industry transactions involving novel\nADC payload technologies, including Novartis’s agreement to acquire Myricx\nBio and Genentech’s collaboration with DualityBio, as additional evidence of\nstrategic interest by Big Pharma companies in acquiring and developing\nnext-generation payload approaches.\n\nWith this backdrop, Akari’s focus is now on execution.\n\nThe Company continues to advance AKTX-101 through IND-enabling toxicology and\nsafety studies, large-scale GMP manufacturing, and Phase 1 planning, with the\ngoal of initiating clinical development in mid-2027. In parallel, Akari is\nalso continuing discussions with potential strategic partners around PH1 and\nthe broader potential of its payload platform to create a broader pipeline of\nADCs using this novel technology\n\n“Our focus now is execution,” said Mr. Gaslightwala. “We are advancing\nthe work required to move AKTX-101 into the clinic while continuing to explore\nthe broader potential of PH1. We believe successful execution could create\nmultiple opportunities for value creation through AKTX-101, potential\nlicensing of our payload technology, and new concepts such as dual-payload\napproaches based on PH1.”\n\n“We believe Akari has built a differentiated scientific foundation,” Mr.\nGaslightwala added. “The next step is to translate that foundation through\ndisciplined execution and demonstrate the potential of this technology in the\nclinic.”\n\nThe CEO Corner segment is now available here\n(https://www.globenewswire.com/Tracker?data=C93df7rjfMXVbbgREmuGZMIC5FttacdCxFCMHEc7AfY7QnTTEodzl1igsDQyep1repKb-UotFkuuo6N_P8Zm7A==).\n\nAbout Akari Therapeutics\n\nAkari Therapeutics is an oncology biotechnology company developing\nnext-generation antibody drug conjugates (ADCs) with a unique payload, PH1,\nwhich targets RNA splicing. Utilizing its innovative ADC discovery platform,\nthe Company has the ability to generate ADC candidates and optimize them based\non the desired application to any antigen target of interest. Akari’s lead\ncandidate, AKTX-101, targets the Trop2 receptor on cancer cells with a\nproprietary linker, enabling it to deliver its novel PH1 payload directly into\nthe tumor with minimal off-target effects. Unlike current ADCs that use\nmicrotubule inhibitors and DNA-damaging agents as their payloads, PH1 is a\nnovel payload that is a spliceosome modulator designed to disrupt RNA splicing\nwithin cancer cells. This splicing modulation has been shown in preclinical\nanimal models to induce cancer cell death while activating both the innate and\nadaptive immune systems to drive robust and durable activity. In preclinical\nstudies, AKTX-101 has been shown to have significant activity and prolonged\nsurvival relative to ADCs with traditional payloads. Additionally, AKTX-101\nhas the potential to be synergistic with checkpoint inhibitors and has\ndemonstrated prolonged survival as both a single agent and in combination with\ncheckpoint inhibitors. The PH1 payload has also been demonstrated to be very\nactive against cancer cells with key oncogenic drivers such as KRAS, BRAF,\nAR-V7, FGFR3 fusions, and others. The Company has initiated IND enabling\nstudies for AKTX-101 with a goal of starting its First-In-Human trial by\nmid-2027. Akari is also developing AKTX-102, an ADC candidate targeting\nCEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a\nwell-validated tumor antigen broadly expressed across multiple solid tumors.\nAKTX-102 is designed to leverage Akari’s proprietary PH1\nspliceosome-modulating payload and a novel antibody construct to enable\ndifferentiated tumor cell killing and immune activation.\n\nFor more information about the Company, please visit www.akaritx.com and\nconnect on X\n(https://www.globenewswire.com/Tracker?data=vd8MLE_tNsp3klYcYKwFSXZS23Sg0NnU1qOyFRLSGXwGCylSHPp0w4Gz2TKGMpBPbnpXFqPyqLbmELY0gEsKWw==)\nand LinkedIn\n(https://www.globenewswire.com/Tracker?data=_PwuXCBLGMv6w5hA9SG8CeqvB17sZG4_CVLt_WgxLWhg1323Eq8oJNHQnlFXxvy9glwPqC_D9SJ7T37z39HOwKxhj2ojmLCQlaG34MfZ0aA=).\n\nCautionary Note Regarding Forward-Looking Statements\n\nThis press release includes express or implied forward-looking statements\nwithin the meaning of Section 27A of the Securities Act of 1933, as amended,\nand Section 21E of the Securities Exchange Act of 1934, as amended, about the\nCompany that involve risks and uncertainties relating to future events and the\nfuture performance of the Company. Actual events or results may differ\nmaterially from these forward-looking statements. Words such as “will,”\n“could,” “would,” “should,” “expect,” “plan,”\n“anticipate,” “intend,” “believe,” “estimate,” “predict,”\n“project,” “potential,” “continue,” “future,”\n“opportunity” “will likely result,” “target,” variations of such\nwords, and similar expressions or negatives of these words are intended to\nidentify such forward-looking statements, although not all forward-looking\nstatements contain these identifying words. Examples of such forward-looking\nstatements include, but are not limited to, express or implied statements\nregarding the potential characteristics and therapeutic applications of PH1\nand PH1-based ADCs, the ability of the Company to advance its product\ncandidates for the treatment of cancer and the timing of a filing of an IND\nand commencement of a Phase I clinical trial. These statements are based on\nthe Company’s current plans, estimates and projections. By their very\nnature, forward-looking statements involve inherent risks and uncertainties,\nboth general and specific. A number of important factors, including those\ndescribed in this communication, could cause actual results to differ\nmaterially from those contemplated in any forward-looking statements. Factors\nthat may affect future results and may cause these forward-looking statements\nto be inaccurate include, without limitation: the Company’s need for\nadditional capital; the potential impact of unforeseen liabilities, future\ncapital expenditures, revenues, costs, expenses, earnings, synergies, economic\nperformance, indebtedness, financial condition and losses on the future\nprospects, business and management strategies for the management, expansion\nand growth of the business; risks related to global as well as local political\nand economic conditions, including interest rate and currency exchange rate\nfluctuations; potential delays or failures related to research and/or\ndevelopment of the Company’s programs or product candidates; risks related\nto any loss of the Company’s patents or other intellectual property rights;\nany interruptions of the supply chain for raw materials or manufacturing for\nthe Company’s product candidates, including as a result of potential\ntariffs; the nature, timing, cost and possible success and therapeutic\napplications of product candidates being developed by the Company and/or its\ncollaborators or licensees; the extent to which the results from the research\nand development programs conducted by the Company, and/or its collaborators or\nlicensees may be replicated in other studies and/or lead to advancement of\nproduct candidates to clinical trials, therapeutic applications, or regulatory\napproval; uncertainty of the utilization, market acceptance, and commercial\nsuccess of the Company’s product candidates; risks related to competition\nfor the Company’s product candidates; and the Company’s ability to\nsuccessfully develop or commercialize its product candidates. While the\nforegoing list of factors presented here is considered representative, no list\nshould be considered to be a complete statement of all potential risks and\nuncertainties. More detailed information about the Company and the risk\nfactors that may affect the realization of forward-looking statements is set\nforth in the Company’s filings with the SEC, copies of which may be obtained\nfrom the SEC’s website at www.sec.gov. The Company assumes no, and hereby\ndisclaims any, obligation to update the forward-looking statements contained\nin this press release except as required by law.\n\nInvestor Relations Contact\n\nJTC Team, LLC \nJenene Thomas \n908-824-0775 \nAKTX@jtcir.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/8d978f50-07a9-40a3-be69-45f51ccd94d9)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX45qhNl-20261015","title":"Akari Therapeutics CEO Highlights Differentiated ADC Payload Strategy and Path Toward Clinical Development in New CEO Corner","author":"Globe Newswire","ticker":"AKTX","created":"2026-10-15T13:20:00.097Z","tickers":["AKTX"],"exchange":"NASDAQ","article_body":"CEO Abizer Gaslightwala discusses Akari’s novel PH1 payload strategy and\nexecution priorities supporting AKTX-101’s advancement toward planned Phase\n1 clinical development in mid-2027\n\nRecent deal activity and emerging clinical data highlighting limitations of\ncurrent ADC sequencing reinforce the increasing demand for novel ADC payloads\n\nAccess the Akari CEO Corner here\n(https://www.globenewswire.com/Tracker?data=C93df7rjfMXVbbgREmuGZLz-A2_DedJF4abgr_H7ErkWuAhaJxZhV1TqvFUpxzluzEFHQ_kmXgb__sXKmsOjOQ==)\n\nTAMPA, Fla. and LONDON, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics,\nPlc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug\nconjugates (ADCs) with a novel RNA splicing disrupting payload, today released\na new CEO Corner segment featuring President and Chief Executive Officer\nAbizer Gaslightwala discussing the Company’s differentiated ADC payload\nstrategy, recent external validation and the execution priorities supporting\nAKTX-101’s advancement toward planned Phase 1 clinical development in\nmid-2027.\n\nAt the center of the discussion is Akari’s belief that ADC payload\ndifferentiation will become increasingly important as more cancer patients\nreceive ADCs as front-line therapies and develop resistance to the current ADC\npayload classes leaving limited subsequent therapy options. Mr. Gaslightwala\ndiscusses emerging clinical data presented at major medical conferences that\nsequential treatment of ADCs utilizing the same payload class do not provide\nbenefit after treatment relapse. This is a significant growing unmet need and\nis an exclusive opportunity for Akari with its novel ADC payload that current\nand most future ADCs will not be able to access.\n\nAkari is pursuing this exclusive opportunity using its PH1 payload, a novel\nspliceosome-modulating payload, which is designed to disrupt RNA splicing in\ncancer cells through a mechanism distinct from commonly used ADC payload\nclasses.\n\nMr. Gaslightwala also describes recent external engagements and presentations\nat partnering and industry conferences in the US and China, where there was\nsignificant interest in Akari’s ADC payload and its differentiated approach.\n\n“It was important for us to gauge interest and excitement in our novel\npayload technology and its application to ADC therapies in areas of growing\nunmet needs like ADC refractory patients, and I left the conferences even more\nconvicted in our technology, strategy, and execution as a company,” said Mr.\nGaslightwala. “Across recent partner discussions and industry engagement,\nour novel PH1 payload generated meaningful interest and reinforced our belief\nthat differentiated payloads can play an increasingly important role as ADC\ntherapies continue to evolve.”\n\nMr. Gaslightwala also points to recent industry transactions involving novel\nADC payload technologies, including Novartis’s agreement to acquire Myricx\nBio and Genentech’s collaboration with DualityBio, as additional evidence of\nstrategic interest by Big Pharma companies in acquiring and developing\nnext-generation payload approaches.\n\nWith this backdrop, Akari’s focus is now on execution.\n\nThe Company continues to advance AKTX-101 through IND-enabling toxicology and\nsafety studies, large-scale GMP manufacturing, and Phase 1 planning, with the\ngoal of initiating clinical development in mid-2027. In parallel, Akari is\nalso continuing discussions with potential strategic partners around PH1 and\nthe broader potential of its payload platform to create a broader pipeline of\nADCs using this novel technology\n\n“Our focus now is execution,” said Mr. Gaslightwala. “We are advancing\nthe work required to move AKTX-101 into the clinic while continuing to explore\nthe broader potential of PH1. We believe successful execution could create\nmultiple opportunities for value creation through AKTX-101, potential\nlicensing of our payload technology, and new concepts such as dual-payload\napproaches based on PH1.”\n\n“We believe Akari has built a differentiated scientific foundation,” Mr.\nGaslightwala added. “The next step is to translate that foundation through\ndisciplined execution and demonstrate the potential of this technology in the\nclinic.”\n\nThe CEO Corner segment is now available here\n(https://www.globenewswire.com/Tracker?data=C93df7rjfMXVbbgREmuGZMIC5FttacdCxFCMHEc7AfY7QnTTEodzl1igsDQyep1repKb-UotFkuuo6N_P8Zm7A==).\n\nAbout Akari Therapeutics\n\nAkari Therapeutics is an oncology biotechnology company developing\nnext-generation antibody drug conjugates (ADCs) with a unique payload, PH1,\nwhich targets RNA splicing. Utilizing its innovative ADC discovery platform,\nthe Company has the ability to generate ADC candidates and optimize them based\non the desired application to any antigen target of interest. Akari’s lead\ncandidate, AKTX-101, targets the Trop2 receptor on cancer cells with a\nproprietary linker, enabling it to deliver its novel PH1 payload directly into\nthe tumor with minimal off-target effects. Unlike current ADCs that use\nmicrotubule inhibitors and DNA-damaging agents as their payloads, PH1 is a\nnovel payload that is a spliceosome modulator designed to disrupt RNA splicing\nwithin cancer cells. This splicing modulation has been shown in preclinical\nanimal models to induce cancer cell death while activating both the innate and\nadaptive immune systems to drive robust and durable activity. In preclinical\nstudies, AKTX-101 has been shown to have significant activity and prolonged\nsurvival relative to ADCs with traditional payloads. Additionally, AKTX-101\nhas the potential to be synergistic with checkpoint inhibitors and has\ndemonstrated prolonged survival as both a single agent and in combination with\ncheckpoint inhibitors. The PH1 payload has also been demonstrated to be very\nactive against cancer cells with key oncogenic drivers such as KRAS, BRAF,\nAR-V7, FGFR3 fusions, and others. The Company has initiated IND enabling\nstudies for AKTX-101 with a goal of starting its First-In-Human trial by\nmid-2027. Akari is also developing AKTX-102, an ADC candidate targeting\nCEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a\nwell-validated tumor antigen broadly expressed across multiple solid tumors.\nAKTX-102 is designed to leverage Akari’s proprietary PH1\nspliceosome-modulating payload and a novel antibody construct to enable\ndifferentiated tumor cell killing and immune activation.\n\nFor more information about the Company, please visit www.akaritx.com and\nconnect on X\n(https://www.globenewswire.com/Tracker?data=vd8MLE_tNsp3klYcYKwFSXZS23Sg0NnU1qOyFRLSGXwGCylSHPp0w4Gz2TKGMpBPbnpXFqPyqLbmELY0gEsKWw==)\nand LinkedIn\n(https://www.globenewswire.com/Tracker?data=_PwuXCBLGMv6w5hA9SG8CeqvB17sZG4_CVLt_WgxLWhg1323Eq8oJNHQnlFXxvy9glwPqC_D9SJ7T37z39HOwKxhj2ojmLCQlaG34MfZ0aA=).\n\nCautionary Note Regarding Forward-Looking Statements\n\nThis press release includes express or implied forward-looking statements\nwithin the meaning of Section 27A of the Securities Act of 1933, as amended,\nand Section 21E of the Securities Exchange Act of 1934, as amended, about the\nCompany that involve risks and uncertainties relating to future events and the\nfuture performance of the Company. Actual events or results may differ\nmaterially from these forward-looking statements. Words such as “will,”\n“could,” “would,” “should,” “expect,” “plan,”\n“anticipate,” “intend,” “believe,” “estimate,” “predict,”\n“project,” “potential,” “continue,” “future,”\n“opportunity” “will likely result,” “target,” variations of such\nwords, and similar expressions or negatives of these words are intended to\nidentify such forward-looking statements, although not all forward-looking\nstatements contain these identifying words. Examples of such forward-looking\nstatements include, but are not limited to, express or implied statements\nregarding the potential characteristics and therapeutic applications of PH1\nand PH1-based ADCs, the ability of the Company to advance its product\ncandidates for the treatment of cancer and the timing of a filing of an IND\nand commencement of a Phase I clinical trial. These statements are based on\nthe Company’s current plans, estimates and projections. By their very\nnature, forward-looking statements involve inherent risks and uncertainties,\nboth general and specific. A number of important factors, including those\ndescribed in this communication, could cause actual results to differ\nmaterially from those contemplated in any forward-looking statements. Factors\nthat may affect future results and may cause these forward-looking statements\nto be inaccurate include, without limitation: the Company’s need for\nadditional capital; the potential impact of unforeseen liabilities, future\ncapital expenditures, revenues, costs, expenses, earnings, synergies, economic\nperformance, indebtedness, financial condition and losses on the future\nprospects, business and management strategies for the management, expansion\nand growth of the business; risks related to global as well as local political\nand economic conditions, including interest rate and currency exchange rate\nfluctuations; potential delays or failures related to research and/or\ndevelopment of the Company’s programs or product candidates; risks related\nto any loss of the Company’s patents or other intellectual property rights;\nany interruptions of the supply chain for raw materials or manufacturing for\nthe Company’s product candidates, including as a result of potential\ntariffs; the nature, timing, cost and possible success and therapeutic\napplications of product candidates being developed by the Company and/or its\ncollaborators or licensees; the extent to which the results from the research\nand development programs conducted by the Company, and/or its collaborators or\nlicensees may be replicated in other studies and/or lead to advancement of\nproduct candidates to clinical trials, therapeutic applications, or regulatory\napproval; uncertainty of the utilization, market acceptance, and commercial\nsuccess of the Company’s product candidates; risks related to competition\nfor the Company’s product candidates; and the Company’s ability to\nsuccessfully develop or commercialize its product candidates. While the\nforegoing list of factors presented here is considered representative, no list\nshould be considered to be a complete statement of all potential risks and\nuncertainties. More detailed information about the Company and the risk\nfactors that may affect the realization of forward-looking statements is set\nforth in the Company’s filings with the SEC, copies of which may be obtained\nfrom the SEC’s website at www.sec.gov. The Company assumes no, and hereby\ndisclaims any, obligation to update the forward-looking statements contained\nin this press release except as required by law.\n\nInvestor Relations Contact\n\nJTC Team, LLC \nJenene Thomas \n908-824-0775 \nAKTX@jtcir.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/8d978f50-07a9-40a3-be69-45f51ccd94d9)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-15T13:20:00.16247467Z","server_sent_at_ms":1792070400162},"received_at":"2026-10-15T13:20:00.216Z","source_url":null},"analysis":{"id":"158707","press_release_id":"170521","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["promotional CEO Corner, not a data or deal disclosure","preclinical-stage lead asset with clinic entry not expected until mid-2027","forward-looking statements flag the need for additional capital"],"eventType":"clinical_trial","narrative":"Akari Therapeutics released a new CEO Corner segment in which CEO Abizer Gaslightwala outlines the company's differentiated ADC payload strategy built around its novel PH1 spliceosome-modulating payload.\n\nThe company reaffirmed that its lead candidate AKTX-101 is advancing through IND-enabling toxicology, GMP manufacturing, and Phase 1 planning, with the goal of initiating clinical development in mid-2027.\n\nGaslightwala cited Big Pharma deal activity — Novartis's agreement to acquire Myricx Bio and Genentech's collaboration with DualityBio — as evidence of strategic interest in next-generation payload technologies.\n\nAkari is also in discussions with potential strategic partners around the PH1 platform and is developing a second candidate, AKTX-102, targeting CEACAM5.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Promotional CEO update positioning PH1 payload platform amid ADC M&A momentum; no new data or catalyst."},"keyFigures":{"drugName":"AKTX-101","phaseOfTrial":"Preclinical / IND-enabling; First-In-Human targeted mid-2027","customDimensions":{"phase1_target":"mid-2027"}},"quotedText":"It was important for us to gauge interest and excitement in our novel payload technology and its application to ADC therapies in areas of growing unmet needs like ADC refractory patients, and I left the conferences even more convicted in our technology, strategy, and execution as a company","namedEntities":{"people":[{"name":"Abizer Gaslightwala","role":"President and CEO"},{"name":"Jenene Thomas","role":"Investor Relations contact (JTC Team, LLC)"}],"products":["AKTX-101","AKTX-102","PH1 payload"],"companies":[{"name":"Akari Therapeutics, Plc","ticker":"AKTX","relationship":"filer"},{"name":"Novartis","relationship":"industry acquirer (Myricx Bio deal cited as validation)"},{"name":"Myricx Bio","relationship":"acquired company cited as deal validation"},{"name":"Genentech","relationship":"industry partner (DualityBio collaboration cited as validation)"},{"name":"DualityBio","relationship":"collaboration party cited as deal validation"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"Promotional CEO commentary reiterating existing pipeline plans (AKTX-101 IND-enabling studies, Phase 1 targeted mid-2027) with no new clinical data, deal, or financing disclosed. Positive framing but no incremental hard catalyst."},"tickerRelevance":{"others":[],"primary":"AKTX"},"globalImportance":18,"audienceRelevance":25,"eventTypeSecondary":["operations_update"],"importanceComponents":{"tickerTier":"micro-cap biotech","eventGravity":"promotional CEO commentary / pipeline reiteration","sectorWeight":"oncology ADC with M&A tailwind narrative","newInformation":"none — reiterates existing IND/Phase 1 timeline"}},"event_type":"clinical_trial","event_type_secondary":["operations_update"],"sentiment":"bullish","material_impact_score":2,"narrative":"Akari Therapeutics released a new CEO Corner segment in which CEO Abizer Gaslightwala outlines the company's differentiated ADC payload strategy built around its novel PH1 spliceosome-modulating payload.\n\nThe company reaffirmed that its lead candidate AKTX-101 is advancing through IND-enabling toxicology, GMP manufacturing, and Phase 1 planning, with the goal of initiating clinical development in mid-2027.\n\nGaslightwala cited Big Pharma deal activity — Novartis's agreement to acquire Myricx Bio and Genentech's collaboration with DualityBio — as evidence of strategic interest in next-generation payload technologies.\n\nAkari is also in discussions with potential strategic partners around the PH1 platform and is developing a second candidate, AKTX-102, targeting CEACAM5.","key_figures":{"drugName":"AKTX-101","phaseOfTrial":"Preclinical / IND-enabling; First-In-Human targeted mid-2027","customDimensions":{"phase1_target":"mid-2027"}},"named_entities":{"people":[{"name":"Abizer Gaslightwala","role":"President and CEO"},{"name":"Jenene Thomas","role":"Investor Relations contact (JTC Team, LLC)"}],"products":["AKTX-101","AKTX-102","PH1 payload"],"companies":[{"name":"Akari Therapeutics, Plc","ticker":"AKTX","relationship":"filer"},{"name":"Novartis","relationship":"industry acquirer (Myricx Bio deal cited as validation)"},{"name":"Myricx Bio","relationship":"acquired company cited as deal validation"},{"name":"Genentech","relationship":"industry partner (DualityBio collaboration cited as validation)"},{"name":"DualityBio","relationship":"collaboration party cited as deal validation"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-15T13:20:06.576Z","global_importance":18,"audience_relevance":25,"importance_components":{"tickerTier":"micro-cap biotech","eventGravity":"promotional CEO commentary / pipeline reiteration","sectorWeight":"oncology ADC with M&A tailwind narrative","newInformation":"none — reiterates existing IND/Phase 1 timeline"}},"durationMs":6350,"modelName":"glm-5.3-flashx"}}